Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world’s leading biotech companies operating in every region of the globe. Acquired by Sanofi in 2011, Sanofi Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology.
Peter Brenders, general manager of Sanofi Genzyme Canada, highlights the strategic significance of the Canadian affiliate, which has seen double-digit growth every quarter for the past five and a half…
Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, highlights the achievements of the company’s Rare Humanitarian Program over the last 30 years, bringing treatments to patients in developing…
2020 was a challenging year globally, but one in which the importance of the healthcare and life sciences sector was underlined like never before. Despite lockdowns and travel restrictions, PharmaBoardroom…
The top 10 most-read interviews on PharmaBoardroom in 2020 represents the broad geographic scope we have had in the past year. From Mexico to Morocco and Romania to Riyadh, these…
Speaking exclusively to PharmaBoardroom, Sanofi Genzyme Executive VP Bill Sibold outlines Sanofi’s strategy for its specialty care unit, the wealth of potential breakthrough assets in its pipeline, product launch strategies,…
Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way.…
Peter Brenders, general manager of Sanofi Genzyme Canada, highlights the strategic significance of the Canadian affiliate, which has seen double-digit growth every quarter for the past five and a half…
The Head of Sanofi-Genzyme’s Czech & Slovak affiliate points out that his affiliate generates a third of the regional turnover for the group as rules and regulations in his market…
Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system…
We use cookies to ensure that we give you the best experience on our site. For more info